# US 2025/0154505 A1 · Effector proteins and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154505 A1
- Document ID: US20250154505A1
- Status: Published application
- Kind: A1
- Application number: 18/920,678
- Filed: 2024-10-18
- Published: 2025-05-15
- Earliest claimed: 2021-05-10
- Assignees: Mammoth Biosciences, Inc.
- Applicants: Mammoth Biosciences, Inc.
- Inventors: Rohan GROVER; Clarissa Oriel RHINES; Aaron DELOUGHERY; Benjamin Julius RAUCH; William Douglass WRIGHT; David PAEZ-ESPINO; Lucas Benjamin HARRINGTON
- Web page: https://patentgrep.com/patent/US20250154505A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

## Claims

### Claim at position 1

-54. (canceled)

### Claim 55

A composition comprising an effector protein, or a nucleic acid encoding the effector protein, wherein the effector protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 23, and wherein the effector protein comprises one or more amino acid substitutions selected from A110R, T111R, E112R, M113R, S114R, T115R, Q116R, S117R, L118R, S119R, F122R, A123R, T124R, E125R, L126R, E127R, T128R, N129R, 1130R, F131R, A132R, K261R, V263R, V264R, G265R, V266R, D267R, D267A, D267N, L268R, G269R, I270R, N271R, V272R, P273R, A274R, Y275R, V276R, A277R, T278R, N279R, 1280R, T281R, E282R, E363Q, E363A, D450A, D450N, 1457R, A458R, N459R, S460R, K461R, D462R, I463R, 1464R, K466R, N467R, E468R, and any combination thereof.

### Claim 56 (depends on 55)

The composition of claim 55, wherein the amino acid sequence is at least 95% identical to SEQ ID NO: 23.

### Claim 57 (depends on 55)

The composition of claim 55, comprising a guide nucleic acid or nucleic acid encoding the same.

### Claim 58 (depends on 57)

The composition of claim 57, wherein the guide nucleic acid comprises a nucleotide sequence that is at least 85% identical to a sequence selected from SEQ ID NO: 624, 628, 630, 634, 638, 641, 643, and 645.

### Claim 59 (depends on 55)

The composition of claim 55, wherein the effector protein comprises one or more amino acid substitutions selected from D267A, E363A, D450A, D267N, E363Q, and D450N.

### Claim 60 (depends on 55)

The composition of claim 55, comprising a partner protein or nucleic acid encoding the same.

### Claim 61 (depends on 60)

The composition of claim 60, wherein the partner protein is selected from a deaminase, a methyltransferase, and a reverse transcriptase.

### Claim 62 (depends on 59)

The composition of claim 59, comprising a partner protein or nucleic acid encoding the same.

### Claim 63 (depends on 62)

The composition of claim 62, wherein the partner protein is selected from a deaminase, a methyltransferase, and a reverse transcriptase.

### Claim 64 (depends on 55)

The composition of claim 55, wherein the nucleic acid encoding the effector protein comprises an AAV vector.

### Claim 65 (depends on 55)

The composition of claim 55, wherein the AAV vector encodes a guide nucleic acid, wherein the guide nucleic acid comprises a nucleotide sequence that is at least 85% identical to a sequence selected from SEQ ID NO: 624, 628, 630, 634, 638, 641, 643, and 645.

### Claim 66 (depends on 55)

The composition of claim 55, wherein the nucleic acid encoding the effector protein comprises an mRNA.

### Claim 67 (depends on 55)

The composition of claim 55, comprising a lipid nanoparticle (LNP) and a guide nucleic acid, wherein the mRNA and the guide nucleic acid are encapsulated in the LNP.

### Claim 68 (depends on 55)

A pharmaceutical composition comprising the composition of claim 55 and a pharmaceutically acceptable excipient.

### Claim 69 (depends on 55)

A method of modifying a target nucleic acid comprising contacting the target nucleic acid with the composition of claim 55.

### Claim 70 (depends on 55)

A cell comprising or modified by the composition of claim 55.

### Claim 71 (depends on 66)

A method of treating a disease, comprising administering to a subject in need thereof the composition of claim 66, wherein the guide nucleic acid comprises a spacer sequence that is complementary to a gene associated with the disease.

### Claim 72 (depends on 67)

A method of treating a disease, comprising administering to a subject in need thereof the composition of claim 67, wherein the guide nucleic acid comprises a spacer sequence that is complementary to a gene associated with the disease.

### Claim 73

A guide nucleic acid comprising a nucleotide sequence that is at least 85% identical to a sequence selected from SEQ ID NO: 624, 628, 630, 634, 638, 641, 643, and 645.
